Literature DB >> 19355935

AD vaccines: conclusions and future directions.

Thomas Wisniewski1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19355935      PMCID： PMC3124076          DOI： 10.2174/187152709787847289

Source DB:  PubMed          Journal:  CNS Neurol Disord Drug Targets        ISSN： 1871-5273            Impact factor:   4.388


× No keyword cloud information.
  60 in total

1.  Induction of toll-like receptor 9 signaling as a method for ameliorating Alzheimer's disease-related pathology.

Authors:  Henrieta Scholtzova; Richard J Kascsak; Kristyn A Bates; Allal Boutajangout; Daniel J Kerr; Harry C Meeker; Pankaj D Mehta; Daryl S Spinner; Thomas Wisniewski
Journal:  J Neurosci       Date:  2009-02-11       Impact factor: 6.167

Review 2.  The coming of age of virus-like particle vaccines.

Authors:  Gary T Jennings; Martin F Bachmann
Journal:  Biol Chem       Date:  2008-05       Impact factor: 3.915

3.  Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults.

Authors:  Anne M Fagan; Catherine M Roe; Chengjie Xiong; Mark A Mintun; John C Morris; David M Holtzman
Journal:  Arch Neurol       Date:  2007-01-08

4.  Amyloid-beta peptide remnants in AN-1792-immunized Alzheimer's disease patients: a biochemical analysis.

Authors:  R Lyle Patton; Walter M Kalback; Chera L Esh; Tyler A Kokjohn; Gregory D Van Vickle; Dean C Luehrs; Yu-Min Kuo; John Lopez; Daniel Brune; Isidro Ferrer; Eliezer Masliah; Amanda J Newel; Thomas G Beach; Eduardo M Castaño; Alex E Roher
Journal:  Am J Pathol       Date:  2006-09       Impact factor: 4.307

5.  Vaccination of Alzheimer's model mice with Abeta derivative in alum adjuvant reduces Abeta burden without microhemorrhages.

Authors:  Ayodeji A Asuni; Allal Boutajangout; Henrieta Scholtzova; Elin Knudsen; Yong Sheng Li; David Quartermain; Blas Frangione; Thomas Wisniewski; Einar M Sigurdsson
Journal:  Eur J Neurosci       Date:  2006-11       Impact factor: 3.386

6.  Blocking TGF-beta-Smad2/3 innate immune signaling mitigates Alzheimer-like pathology.

Authors:  Terrence Town; Yasmina Laouar; Christopher Pittenger; Takashi Mori; Christine A Szekely; Jun Tan; Ronald S Duman; Richard A Flavell
Journal:  Nat Med       Date:  2008-06-01       Impact factor: 53.440

7.  Antibody response and plasma Abeta1-40 levels in young Microcebus murinus primates immunized with Abeta1-42 and its derivatives.

Authors:  Stéphanie G Trouche; Ayodeji Asuni; Sylvie Rouland; Thomas Wisniewski; Blas Frangione; Jean-Michel Verdier; Einar M Sigurdsson; Nadine Mestre-Francés
Journal:  Vaccine       Date:  2008-12-27       Impact factor: 3.641

8.  Short amyloid-beta (Abeta) immunogens reduce cerebral Abeta load and learning deficits in an Alzheimer's disease mouse model in the absence of an Abeta-specific cellular immune response.

Authors:  Marcel Maier; Timothy J Seabrook; Noel D Lazo; Liying Jiang; Pritam Das; Christopher Janus; Cynthia A Lemere
Journal:  J Neurosci       Date:  2006-05-03       Impact factor: 6.167

Review 9.  Recent developments in Alzheimer's disease therapeutics.

Authors:  Michael S Rafii; Paul S Aisen
Journal:  BMC Med       Date:  2009-02-19       Impact factor: 8.775

10.  Reducing AD-like pathology in 3xTg-AD mouse model by DNA epitope vaccine - a novel immunotherapeutic strategy.

Authors:  Nina Movsesyan; Anahit Ghochikyan; Mikayel Mkrtichyan; Irina Petrushina; Hayk Davtyan; Purevdorj B Olkhanud; Elizabeth Head; Arya Biragyn; David H Cribbs; Michael G Agadjanyan
Journal:  PLoS One       Date:  2008-05-07       Impact factor: 3.240
View more
  7 in total

1.  Comparison of Efficacy of Preventive and Therapeutic Vaccines Targeting the N Terminus of β-Amyloid in an Animal Model of Alzheimer's Disease.

Authors:  Irina Petrushina; Hayk Davtyan; Armine Hovakimyan; Arpine Davtyan; Giselle F Passos; David H Cribbs; Anahit Ghochikyan; Michael G Agadjanyan
Journal:  Mol Ther       Date:  2017-01-04       Impact factor: 11.454

Review 2.  Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature.

Authors:  Peter T Nelson; Irina Alafuzoff; Eileen H Bigio; Constantin Bouras; Heiko Braak; Nigel J Cairns; Rudolph J Castellani; Barbara J Crain; Peter Davies; Kelly Del Tredici; Charles Duyckaerts; Matthew P Frosch; Vahram Haroutunian; Patrick R Hof; Christine M Hulette; Bradley T Hyman; Takeshi Iwatsubo; Kurt A Jellinger; Gregory A Jicha; Enikö Kövari; Walter A Kukull; James B Leverenz; Seth Love; Ian R Mackenzie; David M Mann; Eliezer Masliah; Ann C McKee; Thomas J Montine; John C Morris; Julie A Schneider; Joshua A Sonnen; Dietmar R Thal; John Q Trojanowski; Juan C Troncoso; Thomas Wisniewski; Randall L Woltjer; Thomas G Beach
Journal:  J Neuropathol Exp Neurol       Date:  2012-05       Impact factor: 3.685

Review 3.  A fresh perspective from immunologists and vaccine researchers: active vaccination strategies to prevent and reverse Alzheimer's disease.

Authors:  Michael G Agadjanyan; Nikolai Petrovsky; Anahit Ghochikyan
Journal:  Alzheimers Dement       Date:  2015-07-17       Impact factor: 21.566

4.  A cyclic undecamer peptide mimics a turn in folded Alzheimer amyloid β and elicits antibodies against oligomeric and fibrillar amyloid and plaques.

Authors:  Peter Hoogerhout; Willem Kamphuis; Humphrey F Brugghe; Jacqueline A Sluijs; Hans A M Timmermans; Janny Westdijk; Gijsbert Zomer; Claire J P Boog; Elly M Hol; Germie P J M van den Dobbelsteen
Journal:  PLoS One       Date:  2011-04-19       Impact factor: 3.240

5.  Testing a MultiTEP-based combination vaccine to reduce Aβ and tau pathology in Tau22/5xFAD bigenic mice.

Authors:  Hayk Davtyan; Armine Hovakimyan; Sepideh Kiani Shabestari; Tatevik Antonyan; Morgan A Coburn; Karen Zagorski; Gor Chailyan; Irina Petrushina; Olga Svystun; Emma Danhash; Nikolai Petrovsky; David H Cribbs; Michael G Agadjanyan; Mathew Blurton-Jones; Anahit Ghochikyan
Journal:  Alzheimers Res Ther       Date:  2019-12-17       Impact factor: 6.982

Review 6.  Neuronal death in Alzheimer's disease and therapeutic opportunities.

Authors:  Rossen Donev; Martin Kolev; Bruno Millet; Johannes Thome
Journal:  J Cell Mol Med       Date:  2009-09-01       Impact factor: 5.310

Review 7.  Characterization and preclinical evaluation of the cGMP grade DNA based vaccine, AV-1959D to enter the first-in-human clinical trials.

Authors:  Irina Petrushina; Armine Hovakimyan; Indira S Harahap-Carrillo; Hayk Davtyan; Tatevik Antonyan; Gor Chailyan; Konstantin Kazarian; Maxim Antonenko; Amandine Jullienne; Mary M Hamer; Andre Obenaus; Olga King; Karen Zagorski; Mathew Blurton-Jones; David H Cribbs; Harry Lander; Anahit Ghochikyan; Michael G Agadjanyan
Journal:  Neurobiol Dis       Date:  2020-02-28       Impact factor: 5.996
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.